NCT06167317View on ClinicalTrials.gov

Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

254

Participants

Timeline

Start Date

January 9, 2024

Primary Completion Date

September 30, 2028

Study Completion Date

September 30, 2028

Conditions
Advanced Solid Tumors
Interventions
DRUG

GS-0201

Pill administered orally

DRUG

Sacituzumab Govitecan

Administered intravenously

Trial Locations (7)

31096

RECRUITING

Rambam Health Care Campus, Haifa

52621

RECRUITING

Chaim Sheba Medical Center, Tel Litwinsky

75039

RECRUITING

NEXT Dallas, Irving

77030

RECRUITING

The University of Texas MD Anderson Cancer Center, Houston

78758

RECRUITING

NEXT Austin, Austin

6423906

RECRUITING

Tel Aviv Sourasky Medical Center, Tel Aviv

02459

RECRUITING

Dana-Farber Cancer Institute, Boston

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY